MCID: SJG008
MIFTS: 65

Sjogren Syndrome

Categories: Bone diseases, Immune diseases, Rare diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Sjogren Syndrome

MalaCards integrated aliases for Sjogren Syndrome:

Name: Sjogren Syndrome 57 11 19 16
Sjogren's Syndrome 11 42 41 43 14 71
Sicca Syndrome 57 11 19 42 71 33
Sjögren Syndrome 42 75 33
Keratoconjunctivitis Sicca 42 71
Sjogren-Gougerot Syndrome 19 42
Sjögren's Syndrome 52 75
Keratoconjunctivitis Sicca-Xerostomia 42
Secreto-Inhibitor-Xerodermostenosis 42
Dacryosialoadenopathia Atrophicans 42
Primary Sjogren-Gougerot Syndrome 58
Gougerot-Houwer-Sjogren Syndrome 42
Gougerot-Sjogren Syndrome 42
Sjogrens Syndrome Primary 53
Primary Sjogren Syndrome 58
Dry Eye Syndromes 71
Sjogrens Syndrome 53
Xerodermosteosis 11

Characteristics:


Inheritance:

Autosomal recessive 57

Prevelance:

Primary Sjogren Syndrome: 1-5/10000 (France, Europe, Norway, Denmark, Taiwan, Province of China, Italy) 6-9/10000 (Greece) 1-9/100000 (United States, Taiwan, Province of China, Greece, Slovenia, Worldwide) >1/1000 (Turkey, Brazil) 58

Classifications:

Orphanet: 58  
Rare respiratory diseases
Rare systemic and rhumatological diseases


Summaries for Sjogren Syndrome

MedlinePlus Genetics: 42 Sjögren syndrome is a disorder whose main features are dry eyes and a dry mouth. The condition typically develops gradually beginning in middle adulthood but can occur at any age.Sjögren syndrome is classified as an autoimmune disorder, one of a large group of conditions that occur when the immune system attacks the body's own tissues and organs. In Sjögren syndrome, the immune system primarily attacks the glands that produce tears (the lacrimal glands) and saliva (the salivary glands), impairing the glands' ability to secrete these fluids.Dry eyes may lead to itching, burning, a feeling of sand in the eyes, blurry vision, or intolerance of bright or fluorescent lighting. A dry mouth can feel chalky or full of cotton, and affected individuals may have difficulty speaking, tasting food, or swallowing. Because saliva helps protect the teeth and the tissues of the oral cavity, people with Sjögren syndrome are at increased risk of tooth decay and infections in the mouth.In most people with Sjögren syndrome, dry eyes and dry mouth are the primary features of the disorder, and general health and life expectancy are largely unaffected. However, in some cases the immune system also attacks and damages other organs and tissues. This complication is known as extraglandular involvement. Affected individuals may develop inflammation in connective tissues, which provide strength and flexibility to structures throughout the body. Disorders involving connective tissue inflammation are sometimes called rheumatic conditions. In Sjögren syndrome, extraglandular involvement may result in painful inflammation of the joints and muscles; dry, itchy skin and skin rashes; chronic cough; a hoarse voice; kidney and liver problems; numbness or tingling in the hands and feet; and, in women, vaginal dryness. Prolonged and extreme tiredness (fatigue) severe enough to affect activities of daily living may also occur in this disorder. A small number of people with Sjögren syndrome develop lymphoma, a blood-related cancer that causes tumor formation in the lymph nodes but can spread to other organs.Some individuals who are first diagnosed with another rheumatic disorder, such as rheumatoid arthritis or systemic lupus erythematosus, later develop the dry eyes and dry mouth characteristic of Sjögren syndrome. Other autoimmune disorders can also develop after the onset of Sjögren syndrome. In all, about half of all individuals with Sjögren syndrome also have another autoimmune disorder.

MalaCards based summary: Sjogren Syndrome, also known as sjogren's syndrome, is related to mononeuritis multiplex and aplasia of lacrimal and salivary glands, and has symptoms including dryness of eye, eye manifestations and back pain. An important gene associated with Sjogren Syndrome is IFNG-AS1 (IFNG Antisense RNA 1), and among its related pathways/superpathways are Apoptosis and Autophagy and NF-kappaB Signaling. The drugs Fluorometholone and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include eye, salivary gland and skin, and related phenotypes are keratoconjunctivitis sicca and xerostomia

MedlinePlus: 41 Sjogren's syndrome is an autoimmune disease. This means that your immune system attacks parts of your own body by mistake. In Sjogren's syndrome, it attacks the glands that make tears and saliva. This causes a dry mouth and dry eyes. You may have dryness in other places that need moisture, such as your nose, throat, and skin. Sjogren's can also affect other parts of the body, including your joints, lungs, kidneys, blood vessels, digestive organs, and nerves. Most people with Sjogren's syndrome are women. It usually starts after age 40. It is sometimes linked to other diseases such as rheumatoid arthritis and lupus. To make a diagnosis, doctors may use a medical history, physical exam, certain eye and mouth tests, blood tests, and biopsies. Treatment focuses on relieving symptoms. It can differ for each person; it depends on what parts of the body are affected. It may include artificial tears for dye eyes and sucking on sugar-free candy or drinking water often for a dry mouth. Medicines may help with severe symptoms. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

NINDS: 52 Sjögren's syndrome is an autoimmune disorder in which immune cells attack and destroy the glands that produce tears and saliva. Sjögren's syndrome is also associated with rheumatic disorders such as rheumatoid arthritis. The hallmark symptoms of the disorder are dry mouth and dry eyes. In addition, Sjogren's syndrome may cause skin, nose, and vaginal dryness, and may affect other organs of the body including the kidneys, blood vessels, lungs, liver, pancreas, and brain. Sjögren's syndrome affects 1-4 million people in the United States. Most people are more than 40 years old at the time of diagnosis. Women are 9 times more likely to have Sjögren's syndrome than men.

Orphanet: 58 A rare systemic autoimmune disease characterized by exocrine gland dysfunction, resulting predominately in keratoconjunctivitis sicca and xerostomia, but also affecting exocrine glands of the skin, as well as respiratory, urogenital, and digestive tract. Extraglandular manifestations include arthritis, interstitial lung disease, renal disease, and peripheral neuropathy. The disease is accompanied by a substantially increased risk to develop B-cell non-Hodgkin lymphoma, especially MALT (mucosa-associated lymphoid tissue) lymphoma.

GARD: 19 Sjogren syndrome is an autoimmune disorder in which immune cells attack and destroy the glands that produce tears and saliva. Sjogren syndrome is also associated with rheumatic disorders such as rheumatoid arthritis or systemic lupus erythematosus. The hallmark symptoms of Sjogren syndrome are dry mouth and dry eyes. In addition, Sjogren syndrome may cause skin, nose, and vaginal dryness. It also may affect other organs of the body including the kidneys, blood vessels, lungs, liver, pancreas, and brain.

OMIM®: 57 Sjogren syndrome is an autoimmune disease that mainly affects the exocrine glands. It is clinically characterized by keratoconjunctivitis sicca and xerostomia (Goransson et al., 2006). See 200400 for association of Sjogren syndrome with achalasia in sisters. (270150) (Updated 24-Oct-2022)

Disease Ontology: 11 An autoimmune disease that involves attack of immune cells which destroy the exocrine glands that produce tears and saliva.

Wikipedia: 75 Sjögren syndrome or Sjögren's syndrome (SjS, SS) is a long-term autoimmune disease that affects the... more...

Related Diseases for Sjogren Syndrome

Diseases in the Sjogren Syndrome family:

Sjogren's Syndrome, Juvenile, Secondary to Autoimmune Disease

Diseases related to Sjogren Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1543)
# Related Disease Score Top Affiliating Genes
1 mononeuritis multiplex 32.1 TRIM21 SSB APOH
2 aplasia of lacrimal and salivary glands 32.0 SPTAN1 LTF HSPG2 CHRM3
3 salivary gland disease 32.0 TRIM21 TNFSF13B SSB LTF
4 systemic scleroderma 30.8 TRIM21 TNFSF13B SSB RO60
5 xerophthalmia 30.8 TRIM21 TNFSF13B SSB SPTAN1 RO60
6 diffuse infiltrative lymphocytosis syndrome 30.8 TRIM21 SSB
7 mikulicz disease 30.6 TRIM21 TNFSF13B SSB
8 purpura 30.6 TNFSF13B CD79A APOH
9 dacryoadenitis 30.6 TRIM21 TNFSF13B SSB SPTAN1
10 dry eye syndrome 30.5 TRIM21 SSB SPTAN1 RO60 LTF HSPG2
11 mononeuropathy 30.5 TRIM21 SSB
12 sialadenitis 30.5 TRIM21 TNFSF13B SSB SPTAN1 RO60
13 autoimmune disease 30.5 TRIM21 TNFSF13B RO60 FASLG FAS CD79A
14 parotid disease 30.4 TRIM21 SSB
15 cryoglobulinemia 30.4 TNFSF13B CD79A CD40LG
16 parotitis 30.4 TRIM21 SSB LTF CD79A
17 atrioventricular block 30.3 TRIM21 SSB RO60
18 anemia, autoimmune hemolytic 30.3 TNFSF13B CD40LG APOH
19 immunoglobulin alpha deficiency 30.3 TNFSF13B CD79A CD40LG
20 lupus erythematosus 30.3 TRIM21 SSB RO60 FASLG CD40LG CALR
21 vasculitis 30.3 TNFSF13B LTF CD79A CD40LG APOH
22 immune deficiency disease 30.3 TNFSF13B FASLG FAS CD79A CD40LG
23 common variable immunodeficiency 30.3 TNFSF13B FAS CD79A CD40LG
24 polyclonal hypergammaglobulinemia 30.2 TRIM21 TNFSF13B
25 subacute cutaneous lupus erythematosus 30.2 TRIM21 CALR
26 lymphoid interstitial pneumonia 30.2 TRIM21 TNFSF13B SSB
27 mixed connective tissue disease 30.2 TNFSF13B RNPC3 CD40LG APOH
28 endocardial fibroelastosis 30.2 TRIM21 SSB RO60
29 keratoconjunctivitis sicca 30.2 TRIM21 TNFSF13B SSB SPTAN1 RO60 LTF
30 evans' syndrome 30.2 FAS APOH
31 raynaud disease 30.2 TRIM21 RNPC3 APOH
32 connective tissue disease 30.2 TRIM21 TNFSF13B RNPC3 LTF HSPG2 CD40LG
33 third-degree atrioventricular block 30.2 TRIM21 SSB CALR
34 syphilis 30.2 FAS CD79A CD40LG APOH
35 drug-induced lupus erythematosus 30.2 TRIM21 SSB
36 immunoglobulin g deficiency 30.1 CD79A CD40LG
37 heart block, congenital 30.1 TRIM21 TNFSF13B SSB SPTAN1 RO60 CALR
38 limited scleroderma 30.1 TRIM21 SSB RO60 RNPC3
39 diffuse scleroderma 30.1 TRIM21 RNPC3
40 antiphospholipid syndrome 30.1 CD79A CD40LG APOH
41 rheumatoid arthritis 30.1 TNFSF13B LTF FASLG FAS CD79A CD40LG
42 primary biliary cholangitis 30.1 TRIM21 SSB RNPC3 CD79A CD40LG CALR
43 antisynthetase syndrome 30.1 TRIM21 RO60
44 guillain-barre syndrome 30.1 FAS CD79A CD40LG
45 severe cutaneous adverse reaction 30.0 HSPG2 FASLG FAS
46 hashimoto thyroiditis 30.0 IFNG-AS1 FASLG FAS
47 sporotrichosis 30.0 CD79A CD40LG
48 lymphoproliferative syndrome 30.0 FASLG FAS CD40LG
49 behcet syndrome 30.0 TNFSF13B FAS CD40LG APOH
50 cutaneous lupus erythematosus 30.0 TRIM21 TNFSF13B SSB RO60 RNPC3

Comorbidity relations with Sjogren Syndrome via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Hypothyroidism Ichthyosis Vulgaris
Osteoporosis Postinflammatory Pulmonary Fibrosis
Rheumatoid Arthritis Systemic Lupus Erythematosus

Graphical network of the top 20 diseases related to Sjogren Syndrome:



Diseases related to Sjogren Syndrome

Symptoms & Phenotypes for Sjogren Syndrome

Human phenotypes related to Sjogren Syndrome:

58 30 (show top 50) (show all 86)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 keratoconjunctivitis sicca 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001097
2 xerostomia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000217
3 fatigue 58 30 Frequent (33%) Frequent (79-30%)
HP:0012378
4 anxiety 58 30 Frequent (33%) Frequent (79-30%)
HP:0000739
5 arthralgia 58 30 Frequent (33%) Frequent (79-30%)
HP:0002829
6 tubulointerstitial nephritis 58 30 Frequent (33%) Frequent (79-30%)
HP:0001970
7 parotitis 58 30 Frequent (33%) Frequent (79-30%)
HP:0011850
8 chronic pain 58 30 Frequent (33%) Frequent (79-30%)
HP:0012532
9 polyarticular arthropathy 58 30 Frequent (33%) Frequent (79-30%)
HP:0005195
10 usual interstitial pneumonia 58 30 Frequent (33%) Frequent (79-30%)
HP:0031950
11 muscle weakness 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001324
12 arthritis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001369
13 renal insufficiency 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000083
14 dry skin 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000958
15 vitiligo 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001045
16 thyroiditis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100646
17 biliary cirrhosis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002613
18 thrombocytopenia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001873
19 skin ulcer 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0200042
20 myalgia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0003326
21 lymphoma 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002665
22 purpura 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000979
23 meningitis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001287
24 vasculitis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002633
25 abnormal cerebellum morphology 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001317
26 cutis marmorata 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000965
27 lymphadenopathy 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002716
28 leukopenia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001882
29 myositis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100614
30 optic neuritis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100653
31 functional motor deficit 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0004302
32 raynaud phenomenon 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0030880
33 bronchitis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012387
34 normocytic anemia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001897
35 cryoglobulinemia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100778
36 decreased serum complement c3 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0005421
37 glomerulonephritis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000099
38 erythema nodosum 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012219
39 lymphoproliferative disorder 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0005523
40 nonproductive cough 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0031246
41 arteritis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012089
42 decreased serum complement c4 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0045042
43 normochromic anemia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001895
44 lichenoid skin lesion 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0031452
45 abnormal pulmonary thoracic imaging finding 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0031983
46 vaginal dryness 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0031088
47 abnormality of the peripheral nervous system 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0410008
48 seizure 30 Occasional (7.5%) HP:0001250
49 depression 30 Occasional (7.5%) HP:0000716
50 increased circulating antibody level 30 Occasional (7.5%) HP:0010702

Symptoms via clinical synopsis from OMIM®:

57 (Updated 24-Oct-2022)
Cardiovascular Vascular:
vasculitis

Skeletal:
rheumatoid arthritis

Genitourinary Kidneys:
interstitial nephritis

Head And Neck Mouth:
xerostomia

Immunology:
autoimmune disease

Head And Neck Eyes:
xerophthalmia, more severe in men

Clinical features from OMIM®:

270150 (Updated 24-Oct-2022)

UMLS symptoms related to Sjogren Syndrome:


dryness of eye; eye manifestations; back pain; muscle cramp; sciatica

GenomeRNAi Phenotypes related to Sjogren Syndrome according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00249-S 9.4 CD79A CHRM3 LTF
2 Decreased viability GR00381-A-1 9.4 CD79A CHRM3 LTF
3 Decreased viability GR00381-A-3 9.4 CD79A CHRM3 LTF
4 Decreased viability GR00386-A-1 9.4 CD79A CHRM3
5 Decreased viability GR00402-S-2 9.4 LTF

MGI Mouse Phenotypes related to Sjogren Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 9.47 APOH CALR CD40LG CD79A FAS FASLG

Drugs & Therapeutics for Sjogren Syndrome

Drugs for Sjogren Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 309)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorometholone Approved, Investigational Phase 4 426-13-1 9878
2
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
3
Calcium carbonate Approved, Investigational Phase 4 471-34-1
4
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
5
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
6
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
7
Pilocarpine Approved, Investigational Phase 4 54-71-7, 92-13-7 4819 5910
8
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
9
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
10
Sodium fluoride Approved Phase 4 7681-49-4
11
Sorbitol Approved, Investigational Phase 4 69-65-8, 50-70-4 453 6251 5780
12
Allantoin Approved Phase 4 97-59-6 204
13
Dimenhydrinate Approved Phase 4 523-87-5 10660
14
Rebamipide Approved, Investigational Phase 4 90098-04-7 5042
15
Ethanol Approved Phase 4 64-17-5 702
16
Glycerin Approved, Investigational Phase 4 56-81-5 753
17
Bromfenac Approved Phase 4 91714-94-2 60726
18
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
19
Travoprost Approved Phase 4 157283-68-6 5282226
20
Dipivefrin Approved Phase 4 52365-63-6 3105
21
Menthol Approved, Experimental Phase 4 1490-04-6, 2216-51-5, 15356-60-2 1254 16666 165675
22
Povidone K30 Approved, Experimental Phase 4 9003-39-8 6917 131751496
23
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
24
Tetryzoline Approved Phase 4 84-22-0 5419
25
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
26
Ofloxacin Approved Phase 4 82419-36-1 4583
27
Coal tar Approved Phase 4 8007-45-2
28
Mirabegron Approved Phase 4 223673-61-8 18319735 9865528
29
Oxybutynin Approved, Investigational Phase 4 5633-20-5 4634
30
Hydroxychloroquine Approved Phase 4 118-42-3 3652
31
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
32
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
33
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
34
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
35
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
36
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
37
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
38
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
39
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
40
Azithromycin Approved Phase 4 83905-01-5 447043
41
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
42
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
43
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3 3680
44
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 3003 5743
45
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4 8001-79-4 96919
46
Betaine Approved, Investigational, Nutraceutical Phase 4 6915-17-9, 107-43-7 248
47
Isotretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4, 4759-48-2 5538 444795 5282379
48
Gallopamil Investigational Phase 4 16662-47-8 1234
49
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
50 Anesthetics, Local Phase 4

Interventional clinical trials:

(show top 50) (show all 1097)
# Name Status NCT ID Phase Drugs
1 Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome(CTRIPS): A Prospective, Randomized, Multicenter, Double-Blind Placebo-Controlled Trial Unknown status NCT02370550 Phase 4 Cyclosporin A;Prednisone;Placebo;Calcium carbonate D
2 Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue Unknown status NCT00543166 Phase 4 dehydroepiandrosterone
3 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
4 Eight Week Feasibility Study Enrolling Dry Eye Subjects Confirmed by Four of Seven Dianostic Markers Responding to Nutritional Therapy Unknown status NCT01561040 Phase 4
5 Short-term Supplemental Effect of Preservative-free Low-dose Hyaluronic Acid-containing Salt Solution on Dry Eye Disease - A Randomized, Parallel-group, Double-blind, Controlled Trial Unknown status NCT03888183 Phase 4 salt solution without 0.15% HA;preservative-free 0.15% HA
6 Effect of Intense Pulse Light (IPL) Treatment on Tear Film Osmolarity in Dry Eye Disease (DED) With Meibomian Gland Dysfunction (MGD). Unknown status NCT02992535 Phase 4
7 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
8 A Randomized Masked Evaluation of Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
9 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
10 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
11 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
12 Ocular Micro-vascular Research Base on Functional Slip Lamp Biomicroscopy Unknown status NCT03747614 Phase 4 Fluorometholone
13 An Open Label Comparing the Short Term Efficacy of Lacrisert Unknown status NCT03079271 Phase 4 Lacrisert, 5 Mg Ophthalmic Insert
14 Tear Osmolarity Over Time With Artificial Tears Unknown status NCT01227226 Phase 4 Artificial tears
15 A Phase IV, Prospective, Open-label, Multicentre, Single Arm, 3-month Proof of Concept Study to Assess the Effect of IKERVIS® Eye Drops Administered Once Daily on the Quality of Vision in Dry Eye Disease (DED) Patients With Severe Keratitis Unknown status NCT03237936 Phase 4 1mg/mL ciclosporin
16 Xerostomy Treatment in Patients With Sjogren's Syndrome in Chile :A Double Blind Control Trial Comparing Orally Pilocarpine Drops and Artificial Saliva Completed NCT00438048 Phase 4 Artificial Saliva
17 Immunogenicity and Safety of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases Completed NCT03540823 Phase 4
18 Quality of Life in a Portuguese Population With Primary Sjögren Syndrome Completed NCT03578900 Phase 4 Xeros;Citric Acid based Mouthwash
19 Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention Completed NCT00631358 Phase 4 Maxidex
20 Comparison Between Rebamipide 2% Versus Autologous Serum in the Treatement of the Moderate to Severe Dry Eye Associate With Sjögren Syndrome. Pilot, Crossed, Controled, Randomized And Open Study Completed NCT03608761 Phase 4 Rebamipide
21 Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease Completed NCT02004067 Phase 4 Restasis;Refresh Endura
22 A Randomized, Double-Masked, Comparative Study Versus Systane Ultra UD, to Evaluate the Efficacy and Safety of LO2A Eye Drops for Symptomatic Improvement of Dry Eye in Patients With Sjögren's Syndrome Completed NCT03319420 Phase 4 LO2A eye drops;Systane Ultra UD
23 Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease. Impact of Antirheumatic Treatment on Antibody Response. Completed NCT03762824 Phase 4
24 Phase 4 Study Evaluating Efficacy, Safety and Acceptability of Treatment With a New Salivary Equivalent Compared to Two Moisturizing Mouth Sprays on the Improvement of Dry Mouth Symptoms and Oral Comfort in Patients With Xerostomia. Completed NCT02049112 Phase 4
25 Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops: Prospective Double-Blind Randomized Study Completed NCT01850979 Phase 4 Tacrolimus;Olive Oil
26 Effects of Conventional Dry Eye Treatments on the Ocular Surface Response to Low Humidity Environment in Patients With Keratoconjunctivitis Sicca. Completed NCT01797822 Phase 4 Dexamethasone;Artificial tear
27 A Single-Center Evaluation of Retaine™ Ophthalmic Emulsion in the Management of Tear Film Stability and Ocular Surface Staining in Patients Diagnosed With Dry Eye Completed NCT02139033 Phase 4 Retaine™
28 A Prospective, Multicenter, Randomized Controlled Study of the Effect of Lotepredol Etabonate on The Initiation of Dry Eye Treatment With Topical Cyclosporine Completed NCT00407043 Phase 4 Lotemax;Restasis
29 A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye Completed NCT02117687 Phase 4 carboxymethylcellulose 0.5%/glycerin 0.9%;sodium hyaluronate 0.18%
30 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4 carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);sodium hyaluronate 0.18% (VISMED® Multi)
31 A Comparative Study of Use of Cyclosporin Eye Before Cataract Surgery for the Prevention of Dry Eye Completed NCT04426240 Phase 4 Cyclosporine microemulsion
32 Intracanalicular Dexamethasone Used in Conjunction With LipiFlow for the Treatment of Meibomian Gland Dysfunction in Patients With Evaporative Dry Eye Disease and Evidence of Clinically Significant Inflammation Completed NCT04413279 Phase 4 Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal Pulsation
33 An 8 Week, Single Masked, Parallel-Group, Exploratory Study Comparing Ocular Surface Signs and Symptoms in Monotherapy Ocular Hypertension or Glaucoma Patients Randomized to Either Xalatan® or Travatan Z® Completed NCT00799682 Phase 4 Xalatan;Travatan Z
34 Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Completed NCT01684436 Phase 4
35 Evaluation of the Effect of Repeated Usage of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With Dry Eye Complaints Completed NCT01543061 Phase 4
36 Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms Completed NCT00761202 Phase 4 A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®;Sodium hyaluronate
37 Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients Completed NCT01682460 Phase 4 Refresh Tears Lubricant Eye Drops (Allergan)
38 Clinical Efficacy of Topical Hydrocortisone 0.335% (Softacort®) in Patients With Chronic Dry Eye Disease and Associated Ocular Surface Inflammation Completed NCT03907865 Phase 4 Softacort
39 A Study of the Effect of Zinc-Hyaluronate on Ocular Surface Sensations in Patients With Dry Eye Completed NCT02951910 Phase 4
40 Evaluation of the Clinical Efficacy of Hyaluronic Acid and Gingko Biloba Eyedrops in the Management of Iatrogenic Dry Eye Disease Induced by Cataract Surgery Completed NCT05002036 Phase 4
41 The Effect of Ocular Surface Lubricant Eyedrops on Lid Parallel Conjunctival Folds (LIPCOF) and Other Signs and Symptoms of Dysfunctional Tear Syndrome Completed NCT01268735 Phase 4 Lubricating eyedrops containing hydroxypropyl-guar
42 The Utility of in Vivo Confocal Microscopy (IVCM) to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With Dry Eye Disease (DED) Completed NCT02120079 Phase 4 Lotemax;Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)
43 A Phase IV Open-Label Clinical Trial to Evaluate the Efficacy of Ikervis® on Clinical Parameters and Molecular/Cellular Biomarkers in Dry Eye Patients With Severe Keratitis Who Have Not Improved Despite Regular Use of Tear Substitutes Before and After Exposure to an Adverse Controlled Environment Completed NCT04492878 Phase 4 IKERVIS®1mg/mL
44 A Prospective, Randomized, Double-Masked, Single Center, Clinical Comparison of the Use of Systane Ultra in the Management of Dry Eyes in Bilateral Eyes Completed NCT00781092 Phase 4
45 Evaluate Artificial Tear Efficacy in Moderate to Severe Dry Eye Completed NCT00724412 Phase 4
46 A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products Completed NCT02014922 Phase 4 TheraTears® Lubricant Eye Drop;TheraTears® preservative-free single-use containers
47 Evaluation of the Efficacy and Safety of a Treatment for Dry Eye Syndrome: Thealoz Completed NCT01742884 Phase 4
48 An Open-Label, Single-Center Study to Evaluate Symptom Response and Tear Film Cooling Dynamics of Normal and Dry Eye Patients Secondary to Application of a Menthol-Containing Eyedrop (Rohto® Hydra) Completed NCT02985827 Phase 4 Rohto (r) Hydra;Systane (r) Ultra
49 The Effect of Kynex Versus Refresh Plus in Subjects With Mild to Moderate Dry Eye - A Parallel Group, Randomized, Masked Study Completed NCT00809198 Phase 4
50 The Comparison of 50 % Concentration Autologous Serum Eye Drops Versus Preservative Free Artificial Eye Drop Plus 0.05 % Cyclosporin Ophthalmic Emulsion in the Treatment of Severe Dry Eye Syndrome: A Randomized Comparative Study Completed NCT03666884 Phase 4 COE 2*1 (Restasis) + PFAT Refresh Single dose) 8*1

Search NIH Clinical Center for Sjogren Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :


hydroxyethyl cellulose
Linolenic Acid
Sodium Chloride
SODIUM CHLORIDE 0.9% PROCESSING SOLN
SODIUM CHLORIDE GRANULES

Cochrane evidence based reviews: sjogren's syndrome

Genetic Tests for Sjogren Syndrome

Anatomical Context for Sjogren Syndrome

Organs/tissues related to Sjogren Syndrome:

MalaCards : Eye, Salivary Gland, Skin, Lung, Pancreas, Liver, Thyroid

Publications for Sjogren Syndrome

Articles related to Sjogren Syndrome:

(show top 50) (show all 18192)
# Title Authors PMID Year
1
Defective cellular trafficking of lacrimal gland aquaporin-5 in Sjögren's syndrome. 53 62 57
11247557 2001
2
Complement genes contribute sex-biased vulnerability in diverse disorders. 62 57
32499649 2020
3
Ocular complications of primary Sjögren syndrome in men. 62 57
26093285 2015
4
Sjögren's syndrome-like disease in mice with T cells lacking class 1A phosphoinositide-3-kinase. 62 57
17071741 2006
5
Peripheral neuropathy in primary sjogren syndrome: a population-based study. 62 57
17101831 2006
6
A T cell intrinsic role of Id3 in a mouse model for primary Sjogren's syndrome. 62 57
15485632 2004
7
Vogt-Koyanagi-Harada syndrome and keratoconjunctivitis sicca. 62 57
15059728 2004
8
In primary Sjögren's syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response. 62 57
12905478 2003
9
Primary Sjögren's syndrome and deficiency of ICA69. 62 57
12383988 2002
10
Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. 62 57
11879137 2002
11
Impaired neurotransmitter release from lacrimal and salivary gland nerves of a murine model of Sjögren's syndrome. 62 57
11274068 2001
12
Flow cytometric analysis of conjunctival epithelium in ocular rosacea and keratoconjunctivitis sicca. 62 57
11013183 2000
13
Regulation of human leukocyte antigen expression in human conjunctival epithelium. 62 57
9888423 1999
14
Primary Sjögren's syndrome and other autoimmune diseases in families. Prevalence and immunogenetic studies in six kindreds. 62 57
6437309 1984
15
Genetic differences between primary and secondary sicca syndrome. 62 57
314586 1979
16
Familial Sjögren's syndrome with associated primary salivary gland lymphoma. 62 57
766625 1976
17
Association between a History of herpes zoster and the risk of Sjögren's syndrome: a nationwide, population-based, case-control study. 62 41
36241353 2022
18
Bioinformatics analysis identified immune infiltration, risk and drug prediction models of copper-induced death genes involved in salivary glands damage of primary Sjögren's syndrome. 62 41
36254059 2022
19
The causal relationship between neuromyelitis optica spectrum disorder and other autoimmune diseases. 62 41
36248893 2022
20
Assessing the severity of keratitis sicca with videokeratoscopic indices. 57
12799233 2003
21
Sensitive and robust luminescent profiling of anti-La and other autoantibodies in Sjogren's syndrome. 53 62
19657778 2009
22
Autoantibody and biopsy grading are associated with expression of ICAM-1, MMP-3, and TRAIL in salivary gland mononuclear cells of Chinese patients with Sjogren's syndrome. 53 62
19332626 2009
23
ELISA subtypization of anti-ENA autoantibodies in clinical management of autoimmune diseases in Bosnia and Herzegovina. 53 62
20380108 2009
24
Polymorphism in the 5' regulatory region of the B-lymphocyte activating factor gene is associated with the Ro/La autoantibody response and serum BAFF levels in primary Sjogren's syndrome. 53 62
18617551 2008
25
Altered distribution of aquaporin 5 and its C-terminal binding protein in the lacrimal glands of a mouse model for Sjögren's syndrome. 53 62
18696337 2008
26
The role of interleukin-10 promoter polymorphisms in primary Sjogren's syndrome. 53 62
18612930 2008
27
CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjogren's syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization. 53 62
18354239 2008
28
A fulminant case of renal vein thrombosis in a patient with autoimmune disorder and membranous nephropathy. 53 62
18480584 2008
29
Is SS-A/Ro52 a hydrogen peroxide-sensitive signaling molecule? 53 62
17184176 2007
30
Prognostic value of auto-antibodies in the serum of Omani patients with gastric cancer. 53 62
17143367 2006
31
[Prevalence of antiphospholipid antibodies in patients with primary Sjögren's syndrome]. 53 62
17195353 2006
32
[Is pure red cell aplasia a new extra digestive manifestation of celiac disease?]. 53 62
16527376 2006
33
Immunoglobulin VH genes in thymic MALT lymphoma are biased toward a restricted repertoire and are frequently unmutated. 53 62
16353132 2006
34
Distinct profiles of Sjögren's syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF. 53 62
16126006 2005
35
IL-10 promoter -1082 polymorphism is associated with elevated IL-10 levels in control subjects but does not explain elevated plasma IL-10 observed in Sjögren's syndrome in a Hungarian cohort. 53 62
16305644 2005
36
[The role of BAFF in autoimmune diseases]. 53 62
16276047 2005
37
Detection of apoptosis-specific autoantibodies directed against granzyme B-induced cleavage fragments of the SS-B (La) autoantigen in sera from patients with primary Sjögren's syndrome. 53 62
16178869 2005
38
Analysis of in vivo role of alpha-fodrin autoantigen in primary Sjogren's syndrome. 53 62
16192640 2005
39
Identification of specific autoantigens in Sjögren's syndrome by SEREX. 53 62
16108817 2005
40
Immunopathogenesis of primary Sjögren's syndrome: implications for disease management and therapy. 53 62
16093833 2005
41
Are autoantibodies against a 25-mer synthetic peptide of M3 muscarinic acetylcholine receptor a new diagnostic marker for Sjögren's syndrome? 53 62
16014696 2005
42
A novel polymorphism of the SSA1 gene is associated with anti-SS-A/Ro52 autoantibody in Japanese patients with primary Sjögren's syndrome. 53 62
16095123 2005
43
Abnormal distribution of aquaporin-5 in salivary glands in the NOD mouse model for Sjögren's syndrome. 53 62
15940770 2005
44
Prevalence of IgG anti-{alpha}-fodrin antibodies in Sjogren's syndrome. 53 62
16014536 2005
45
BAFF overexpression is associated with autoantibody production in autoimmune diseases. 53 62
16014518 2005
46
Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren's syndrome. 53 62
15981083 2005
47
Reversible cortical lesions in primary Sjögren's syndrome presenting with meningoencephalitis as an initial manifestation. 53 62
15850591 2005
48
Neutralization of muscarinic receptor autoantibodies by intravenous immunoglobulin in Sjögren syndrome. 53 62
15866705 2005
49
Minor gland saliva flow rate and proteins in subjects with hyposalivation due to Sjogren's syndrome and radiation therapy. 53 62
15740707 2005
50
Expression of aquaporin-5 in and fluid secretion from immortalized human salivary gland ductal cells by treatment with 5-aza-2'-deoxycytidine: a possibility for improvement of xerostomia in patients with Sjögren's syndrome. 53 62
15640830 2005

Variations for Sjogren Syndrome

Expression for Sjogren Syndrome

Search GEO for disease gene expression data for Sjogren Syndrome.

Pathways for Sjogren Syndrome

Pathways related to Sjogren Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.61 SPTAN1 FASLG FAS CD40LG
2 11.54 TNFSF13B FASLG FAS CD79A CD40LG
3 11.4 FASLG FAS CD40LG
4 11.18 IFNG-AS1 CD79A CD40LG

GO Terms for Sjogren Syndrome

Biological processes related to Sjogren Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 necroptotic signaling pathway GO:0097527 9.56 FASLG FAS
2 B cell proliferation GO:0042100 9.43 TNFSF13B CD79A CD40LG
3 cell communication GO:0007154 9.33 TNFSF13B FASLG CD40LG
4 signaling GO:0023052 8.8 TNFSF13B FASLG CD40LG

Molecular functions related to Sjogren Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor receptor binding GO:0005164 9.1 TNFSF13B FASLG CD40LG

Sources for Sjogren Syndrome

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....